X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
UNI50001 (orismilast) is a high-potency, oral, next-generation PDE4 inhibitor targeting the PDE4 subtypes linked to inflammation, being developed in patients with hidradenitis suppurativa and also in atopic dermatitis (AD) and psoriasis.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: UNI50001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
UNI50001 (orismilast), a high-potency PDE4 inhibitor linked to inflammation. Orismilast holds the potential to become a safe and efficacious oral treatment for many immunological diseases, and is currently developing oral orismilast for the treatment of AD, psoriasis, and HS.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: UNI50001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
IBI353 (orismilast) is a next-generation PDE4 inhibitor with high potency for the PDE4 subtypes linked to inflammation currently under development as an oral treatment for psoriasis, AD and HS.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: IBI353
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Union Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2022
Details:
Preclinical data demonstrated that UNI50001 (orismilast) is potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are considered more relevant in treatment of immunological diseases.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: UNI50001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
UNION is developing orismilast, which is a potent next-generation phosphodiesterase type-4 (PDE4) inhibitor operating early in the inflammation cascade to induce a broad spectrum of downstream anti-inflammatory effects.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: UNI50001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Under the terms of the agreement, UNION grants Innovent an exclusive license to research, develop and commercialize orismilast in China, including participating in and recruiting Chinese patients for potential future global studies of orismilast.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: UNI50001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: $267.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration September 28, 2021
Details:
Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors. Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis and indicated "best-in-class" potential.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: UNI50001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo.
Lead Product(s): Orismilast
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: UNION therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
